NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer CellsVincenzo Quagliariello, Nicola Maurea, Michelino De Laurentiis et al.|International Journal of Molecular Sciences|2020Cited by 82
SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer PatientsVincenzo Quagliariello, Nicola Maurea, Annamaria Bonelli et al.|Cancers|2020Cited by 28
SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?Vincenzo Quagliariello, Nicola Maurea, Antonietta Caronna et al.|PubMed|2020Cited by 25
1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathwayNicola Maurea, Gerardo Botti, Vincenzo Quagliariello et al.|Annals of Oncology|2020Cited by 7
TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokinesNicola Maurea, Gerardo Botti, Vincenzo Quagliariello et al.|European Heart Journal|2021Cited by 5